Bipolar Disorder (Manic Depression) - Pipeline Review - Research and Markets

DUBLIN--()--Research and Markets (http://www.researchandmarkets.com/research/4qdd6k/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering.

This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases.

It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

  1. Introduction
  2. Bipolar Disorder (Manic Depression) Overview
  3. Therapeutics Development
  4. Pipeline Products for Bipolar Disorder (Manic Depression) - Overview
  5. Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis
  6. Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies
  7. Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes
  8. Bipolar Disorder (Manic Depression) - Pipeline Products Glance
  9. Late Stage Products
  10. Clinical Stage Products
  11. Early Stage Products
  12. Bipolar Disorder (Manic Depression) - Products under Development by Companies
  13. Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes
  14. Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development

Companies Mentioned:

  • Aequus Pharmaceuticals Inc.
  • ANP Technologies, Inc.
  • AstraZeneca Plc
  • Convergence Pharmaceuticals Ltd.
  • D-Pharm Ltd.
  • Delpor, Inc.
  • Intas Pharmaceuticals Ltd.
  • Intra-Cellular Therapies, Inc.
  • Johnson & Johnson
  • KemPharm, Inc.
  • Neurocrine Biosciences, Inc.
  • Omeros Corporation
  • Otsuka Holdings Co., Ltd.
  • Pfizer Inc.
  • Reviva Pharmaceuticals Inc.
  • SK Biopharmaceuticals Co., Ltd.
  • Sumitomo Dainippon Pharma Co., Ltd.
  • Teva Pharmaceutical Industries Limited
  • Zogenix, Inc.
  • Zysis Limited

For more information visit http://www.researchandmarkets.com/research/4qdd6k/bipolar_disorder

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System, Mental Disorders

Contacts

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Sector: Central Nervous System, Mental Disorders